Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
TXG

TXG - 10X Genomics Inc Stock Price, Fair Value and News

$21.08-0.54 (-2.50%)
Market Closed

23/100

TXG

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

23/100

TXG

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$17.9

Target 3M

$20.14

Target 6M

$19.02

TXG Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

TXG Price Action

Last 7 days

-7.0%

Last 30 days

30.5%

Last 90 days

69.5%

Trailing 12 Months

42.1%

TXG RSI Chart

TXG Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

TXG Valuation

Market Cap

2.6B

Price/Earnings (Trailing)

-34.24

Price/Sales (Trailing)

4.07

EV/EBITDA

-57.07

Price/Free Cashflow

32

TXG Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$17.9

Target 3M

$20.14

Target 6M

$19.02

TXG Fundamentals

TXG Revenue

Revenue (TTM)

641.8M

Rev. Growth (Yr)

-1.75%

Rev. Growth (Qtr)

-13.83%

TXG Earnings

Earnings (TTM)

-76.3M

Earnings Growth (Yr)

23.16%

Earnings Growth (Qtr)

-179.54%

TXG Profitability

Operating Margin

68.83%

EBT Margin

-11.39%

Return on Equity

-9.72%

Return on Assets

-7.43%

Free Cashflow Yield

3.12%

TXG Investor Care

Shares Dilution (1Y)

2.68%

Diluted EPS (TTM)

-0.62

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2025624.7M644.5M641.8M0
2024625.4M631.7M629.7M610.8M
2023536.2M568.4M591.0M618.7M
2022499.2M497.9M503.7M516.4M
2021332.8M405.7M459.2M490.5M
2020264.2M251.3M261.9M298.8M
2019172.5M196.6M221.2M245.9M
201889.9M108.7M127.5M146.3M
201700071.1M
Get all data in R, Python etc through our Historical Stock Data APIs

About 10X Genomics Inc

TXG
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell Assay for Transposase Accessible Chromati (ATAC) for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
 CEO
 WEBSITE10xgenomics.com
 SECTORHealthcare
 INDUSTRYHealth Information Services
 EMPLOYEES1243

10X Genomics Inc Frequently Asked Questions

TXG is the stock ticker symbol of 10X Genomics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of 10X Genomics Inc is 2.61 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check TXG's fair value in chart for subscribers.

The fair value guage provides a quick view whether TXG is over valued or under valued. Whether 10X Genomics Inc is cheap or expensive depends on the assumptions which impact 10X Genomics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for TXG.

As of Wed Jan 28 2026, TXG's PE ratio (Price to Earnings) is -34.24 and Price to Sales (PS) ratio is 4.07. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. TXG PE ratio will change depending on the future growth rate expectations of investors.